We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Anadys Pharmaceuticals (MM) | NASDAQ:ANDS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.70 | 0 | 01:00:00 |
www.bedfordreport.com/IDIX
www.bedfordreport.com/ANDS
Both Vertex's Incivek and Merck and Co.'s Victrelis were cleared by the FDA this spring. Analysts argue that both companies could get billions in sales of both drugs. In the third quarter alone, Vertex reported sales of $420 million for Incivek. Hepatitis C is a viral infection that often has no symptoms but which can lead to life-threatening liver damage. Approximately 4 million Americans have the disease.
Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. The Company's lead program, IDX184, is a pan-genotypic oral nucleotide polymerase inhibitor that has shown potent antiviral activity in both preclinical and clinical studies.
The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Last month Switzerland-based Roche Holdings AG agreed to acquire Anadys Pharmaceuticals, a biopharmaceutical company engaged in the development of medicines for the treatment of hepatitis C for $230 million in cash.
In a note to clients, JMP Securities analyst Liisa Bayko said she expects she expects more hepatitis drug developers to be acquired. "We anticipate more deal making in the hepatitis C virus space in 2012 as companies accrue longer-term safety data on the earlier stage assets in the pipeline," she wrote.
The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
1 Year Anadys Chart |
1 Month Anadys Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions